A phase III Chinese trial was designed to investigate survival outcomes, response rates, and safety of patients with advanced HCC (BCLC C stage) treated with PD-1/PD-L1 inhibitors by hepatic artery versus vein infusion (NCT03949231). The gene discussed is CD274; the disease is hepatocellular carcinoma.